Drug Approval | October 30, 2022
USFDA issues Form 483 for Parawada unit of Laurus Labs
The observation is procedural in nature and the company will address the observation within stipulated timelines.
The observation is procedural in nature and the company will address the observation within stipulated timelines.
Indigenously-developed molecular diagnostics have helped expand the reach of diagnosis to every part of the country today
The company's long-term strategy is on science, technology and innovation and the company's strategy relating to this is on track
It allows users to generate cell lines suitable for clinical development without their own starter cells, vectors or prior experience in the field.
The JUMP-CP Consortium’s aim is to validate and scale up image-based drug discovery strategies by creating the world’s largest public cell imaging data set
Gland Pharma Q2 FY2023 consolidated net profit up at Rs. 241.24 Cr
Results reinforce commitment to next-generation oral SERD development programme
Frazier led the company for 10 years as President and Chief Executive Officer, from 2011 through 2021.
Oncodesign Services (ODS ), with 600 clients in 33 countries and 227 employees worldwide, provides services from target identification to hit-to-lead and lead optimization through to IND filing.
Submission based on QuANTUM-First results showing quizartinib plus chemotherapy significantly improved overall survival compared to chemotherapy alone
Subscribe To Our Newsletter & Stay Updated
